background Studies of endovascular renal denervation (RDN) have demonstrated significant blood pressure reduction in eligible patients with resistant hypertension. These trials have used stringent inclusion and exclusion criteria in patient enrollment, potentially selecting for a small subset of patients with resistant hypertension. In this study, we examined the changes in estimated prevalence of resistant hypertension when using increasingly stringent definitions of resistant hypertension in a fixed population and assessed the generalizability of RDN when applying study criteria to a community-based hypertensive population.
Hypertension directly contributes to the morbidity and mortality suffered from myocardial infarction, congestive heart failure, stroke, and end-stage renal disease. [1] [2] [3] This relationship is heightened in those who are resistant to standard therapy. 4 The American Heart Association (AHA) defines resistant hypertension (RH) as "blood pressure (BP) that remains above goal in spite of the concurrent use of 3 antihypertensive agents of different classes. Ideally, one of the 3 agents should be a diuretic and all agents prescribed at optimal dose amounts. " Patients with BP controlled on 4 or more medications are also considered resistant. 5 This definition is arbitrary and serves to identify a subset of hypertensive patients who may benefit from further diagnostic testing and alternative therapeutic measures. Endovascular renal artery sympathetic denervation (RDN) is emerging as a novel, minimally invasive therapy for RH. Preliminary evidence suggests it is safe and effective in lowering BP in a subset of patients with RH. 6, 7 To date, SYMPLICITY HTN-3 is the largest, ongoing, randomized, multicenter trial in the world, seeking to validate the efficacy and safety of RDN. 8 It is, however, unclear which subset of RH patients may benefit from RDN. The true prevalence of RH is unknown, and estimates in the literature are highly variable. Cohort studies and post hoc analyses of randomized controlled trials have estimated a prevalence of RH of 3.0%-34.3%. 3, 4, [9] [10] [11] [12] [13] [14] [15] [16] [17] These studies have used inconsistent variations of the AHA definition of RH, often not requiring that the medication regimen include a diuretic or be maximally dosed. It is possible that reported intrastudy variability in the prevalence estimates of RH is mainly due to differences in each study's interpretation of the definition of RH. Published studies of RDN in RH patients, on the other hand, have employed inclusion and exclusion criteria that are more stringent than the AHA definition. [6] [7] [8] As a result, the wide range in estimated prevalence of RH makes it unclear what proportion of hypertensive patients seen in the outpatient setting are truly resistant and whether observed variations are merely the result of differences in interpretation of the definition. Of the patients truly deemed resistant, it is also uncertain how many qualify for RDN given the stringent methodologic criteria employed in RDN studies. The objective of this retrospective, cross-sectional study was to demonstrate the variability in estimated prevalence of RH when applying increasingly stringent prespecified interpretations of the AHA definition to an outpatient population and to compare this to the proportion of out patient hypertensive patients that would qualify for RDN based on published criteria in the same population. We also sought to describe demographic and clinical differences between RDN eligible and noneligible patients.
METHODS
Electronic medical records of all consecutive outpatient visits to the cardiology clinics of the Emory Clinic at Emory University Hospital Midtown were reviewed from September 2011 to March 2012. Emory University Hospital Midtown is a tertiary care medical center based in an urban setting. All patients with the diagnosis of hypertension were identified. For patients with multiple visits, the most recent visit was used as the index visit for data analysis. Patients with known secondary causes of RH or documented as being noncompliant in their medical record as either part of the problem list or in the clinician's note were excluded. Demographics, relevant clinical characteristics, vital signs, height, weight, medication class, and dosages recorded at the index visit were collected. BP measurements were performed by clinical ancillary staff, properly trained with the use of calibrated automated BP devices that were consistently used in all patients. If a physician repeated the BP measurement manually, this recording was substituted for the clinic staff measurement. Creatinine clearance was calculated using the Cockcroft-Gault equation and the latest creatinine value documented within 12 months of the index visit.
The prevalence of RH was evaluated by applying four different definitions of increasing stringency to the same population ( Table 1 ). The different terms and variations of the definition used in this study are as follows: Controlled refers to patients with BP at goal on <4 medications. Uncontrolled hypertension refers to patients with BP not at goal on <3 medications. Goal BP was defined as BP ≤140/90 mm Hg or <130/80 mm Hg for patients with diabetes and chronic kidney disease, which for the purpose of this study was defined by a creatinine clearance <60 ml/min. RH refers to patients with BP not at goal on 3 medications or controlled on 4 medications regardless of dosage. RH + D refers to RH patients who were on a diuretic as part of their medication regimen. RH Max refers to RH patients on 3 maximally-dosed medications or controlled on 4 medications, at least 3 of which were maximally dosed. The dose of an antihypertensive was considered maximal when it conformed to the dosage defined in the seventh report of the Joint National Committee. 18 RH Max + D refers to RH patients on a maximally dosed regimen, 1 of which had to be a diuretic. Eligibility for RDN was defined on the following published criteria from the SYMPLICITY HTN-3 study: aged 18-80 years, systolic BP ≥160 mm Hg at index visit, creatinine clearance ≥45 ml/min with no known renal artery stenosis or prior renal artery intervention, and a medication regimen including at least 3 maximally dosed antihypertensive agents including 1 diuretic. 8 SAS version 9.2 (SAS Institute, Cary, NC) for Windows was used for data analysis. Differences for continuous variables between the defined group and the rest of the population were evaluated using the 2-tailed t test or Wilcoxon test when appropriate. Differences in categorical variables were assessed using the χ 2 test. Means were reported with the associated SD. A 2-sided P value <0.05 denoted statistical significance. This study was conducted in accordance with institutional review board approval and the Health Insurance Portability and Accountability Act.
RESULTS
A total of 1,792 patients with a diagnosis of hypertension were identified over a 6-month study period. Thirty-six Variants of the definition of resistant hypertension and their criteria listed by increasing stringency. Abbreviations: CrCl, creatinine clearance; RAS, renal artery stenosis; RDN, patients meeting eligibility criteria for renal denervation; RH, patients with BP not at goal on 3 medications or controlled on 4 medications regardless of dosage; RH+D, RH patients whom are also on a diuretic as part of their medication regimen; RH Max, RH patients on at least 3 maximally dosed medications; RH Max + D, RH patients on a maximally dosed regimen, 1 of which is a diuretic; SBP, systolic blood pressure.
patients with documented noncompliance were excluded from the study, leaving a final population of 1,756. Creatinine values were available for 1,562 patients. Among the 1,756 hypertensive outpatients, 762 (43.4%) had appropriate BP control, whereas 451 (25.6%) were uncontrolled on <3 medications. The estimated prevalence of RH per definition is depicted in Figure 1 . Patients considered resistant to antihypertensive treatment by the most lenient definition (RH) represented 30.9% of the population (543 patients). The requirement of a diuretic as part of the medication regimen (RH+D) decreased that estimate to 15.3% (268 patients). The estimated prevalence of RH dropped to only 4.7% (83 patients) when optimal medication dosing was included as a criterion in defining resistant hypertension (RH Max). The most stringent definition, requiring optimal dosing of all medications and the presence of a diuretic (RH Max+D), classified only 3.4% of the population (60 patients) as resistant. Only 0.8% (14 patients) met eligibility criteria for RDN. Among the 46 patients with RH Max+D who were not RDN eligible, 42 had a SBP < 160, 7 had a GFR < 45, 4 were older than 80 years, and 1 had renal artery stenosis.
The study population was composed of 55.0% male, 53.9% white, and 38.6% black patients, with a mean age of 66.6 years (SD = 12.5) and body mass index of 30.1 kg/m 2 (SD = 10.7). Table 2 provides the demographics, clinical characteristics, and medication use of these patients stratified by BP control and definition of RH. Patients considered eligible for RDN were more likely to be female, black, and have a higher body mass index than the rest of the study population (P < 0.05).
Overall, the frequency of comorbidities in the study population was as follows: 30.9% of patients were diabetics, 49.7% had known coronary artery disease, 30.4% suffered from congestive heart failure, and 10.1% suffered from prior stroke. Chronic kidney disease as previously defined was present in 24.0% of the study population. The frequencies of comorbidities among patients falling under each RH definition are in Table 2 . A diagnosis of congestive heart failure was more frequent in patients eligible for RDN. Table 3 provides the number of antihypertensive medications used by medication class for patients in each hypertension definition. Diuretics were included in the medication regimen of 48.9% of patients, with 62.7% of patients receiving the thiazide type. Both β-blocker and renin-angiotensin system antagonist usage was common (67.1% and 68.4%, respectively). Of the patients receiving renin-angiotensin system antagonists, 67.3% were receiving angiotensin-converting enzyme (ACE) inhibitors. Calcium channel blockers were less commonly used (34.7%). All 4 of these antihypertensive classes were used more frequently by patients with RH across definitions. Of note, the use of spironolactone in this population was low (3.2%), even in patients eligible for RDN (7.1%). β-blockers includes both selective and nonselective subclasses. Calcium channel blockers included dihydropyridine and nondihydropyridine subclasses. Diuretics include loop, thiazide, and potassium-sparing diuretics. Renin-angiotensin system (RAS) inhibitors include angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blocker (ARB). Centrally acting sympatholytics include clonidine and α-methyldopa. Direct vasodilators include hydralazine and minoxidil. Data presented as mean ± SD or % where appropriate. Abbreviations: RDN, patients meeting eligibility criteria for renal denervation; RH, patients with BP not at goal on 3 medications or controlled on 4 medications regardless of dosage; RH+D, RH patients whom are also on a diuretic as part of their medication regimen; RH Max, RH patients on at least 3 maximally dosed medications; RH Max + D, RH patients on a maximally dosed regimen, 1 of which is a diuretic.
DiSCUSSiOn
This retrospective cross-sectional study of hypertensive outpatients demonstrates that the estimated prevalence of RH varies widely when varying interpretations of the AHA definition of RH are applied to the same population. When applying RDN eligibility criteria, only a few would qualify to receive this novel therapy, with numbers far fewer than would be seen using the strictest interpretation of the RH definition.
In our study population, the estimated prevalence of RH ranged from as high as 28.5% to only 3.3% of patients, depending on the specific definition chosen. Definitions that required maximal dosing of medications to be considered resistant, as used in the definitions RH Max or RH Max+D, resulted in far lower prevalence estimates, demonstrating the importance of medication dosing in characterizing hypertensive resistance. These estimates of 4.7% and 3.4%, respectively, are significantly lower than what has been reported in the literature. Past prospective and retrospective studies examining the prevalence of RH have typically not taken into account maximal medication dosing to define RH and may be overestimating the true prevalence. Randomized controlled trials have protocol-dictated titration of medication regimens to prevent suboptimal dosing. However, they also report much higher estimates of the prevalence of RH than those obtained in our study using maximal dosing criteria. The patients in these trials were typically older, had at least 1 cardiovascular risk factor, and their medication regimens were prespecified and restricted in regard to class, allowable combinations, and dosage, which results in less aggressive attempts at BP control and hereby may explain the higher prevalence estimates.
Applying published inclusion and exclusion criteria of the SYMPLICITY HTN-3 study to our hypertensive population yielded only 14 patients, or 0.8% of the total study population and only 23% of patients classified as RH using the most stringent definition (RH Max+D). The number of RDN-eligible patients may also be overestimated, as the retrospective nature of this study precluded ambulatory BP monitoring and assessment of renal arterial anatomy, as mandated by the SYMPLICITY HTN-3 protocol. 8 Our estimation of RDN eligibility is contrary to prior reports that forecast a higher percentage of the hypertensive population benefiting from RDN. 3, 19 A study in hospitalized patients admitted to a tertiary hypertension center found a low proportion (1.5%) of enrolled patients were eligible for RDN, after excluding those with secondary causes of hypertension and with unsuitable renal anatomy. 20 To our knowledge, our study is the first to comprehensively apply the criteria from RDN studies to an outpatient population and, consistent with the study of inpatients in a tertiary setting, confirms that an even smaller proportion of hypertensive outpatients meet criteria for RDN. Our findings demonstrate that the currently available clinical data demonstrating BP lowering after RDN, although impressive in a select population, are not yet applicable for generalization to the general population of hypertensive patients and are likely relevant to only a small proportion of patients that are currently deemed resistant to standard therapy. Hopefully, future studies of RDN, such as the planned SYMPLICITY HTN-4 study, will confirm a benefit of this therapeutic approach in a broader population of RH patients to allow it to be generalized further. 21 Demographically, this study demonstrates a statistically significant association of RH with obesity, female sex, and black race across all definitions of RH, consistent with what has previously been published. 10, 22 These findings are at odds with those of Daugherty et al., whose analysis showed a higher incidence of RH in those of male sex and white race. 4 Our study's hypertensive population consists of more black patients than many others reported in the literature. Thus, these results may be more generalizable to other similar, predominantly urban clinical practices. Patients eligible for RDN were older (mean age = 69.8 years), mostly women (76.5%), and black (88.2%). This is in stark contrast with the patient population studied in the SYMPLICITY HTN-2 study, who were predominantly younger (mean age = 58 years), white (97%), and male (65%). 6 These numbers would suggest that further evaluation of RDN efficacy in women and patients of black race is warranted, given their underrepresentation in the RDN trials thus far.
Although we demonstrate that the strictest definition of RH is associated with a much lower prevalence than that reported in most other studies, one may ask if the strictest definitions are important clinically. The purpose of identifying a patient resistant to antihypertensive medication depends on who is asking the question. A broader, more inclusive definition may, in fact, be more helpful from a public health standpoint, as it may identify large numbers of patients who may benefit from modification of their lifestyle, pharmacologic therapy, and other risk factors to reduce preventable cardiovascular morbidity. A more restrictive definition, on the other hand, may be important in identifying selective groups of patients who may be experiencing hypertension from unique pathophysiologic mechanisms or who may stand to benefit from unique therapeutic interventions, such as neurohumoral modulation from RDN. It is likely that subgroups that have RH despite maximal medication dosing may respond to antihypertensive treatments differently and may experience different long-term outcomes.
As RH is further studied, consistency in the applied definitions of RH is crucial so that long-term outcomes, unique patient characteristics, and treatment effectiveness of established and novel therapies can be easily interpreted and compared. Our study suggests that several different, strictly defined categories of RH may be helpful in further advancing the science and treatment of hypertension. Future studies evaluating RH in a prospective manner, ideally with dose titration to maximally tolerated doses, would be helpful to clarify the epidemiology of RH and could shed light on the burden of secondary disease that these patients may suffer. In regard to therapy, a wave of future studies are being planned to evaluate the role and efficacy of RDN and other novel interventions effecting autonomic modulation as a treatment modality to lower BP in RH patients. 23 In an era of cost control, consistency in study definitions of RH characteristics will help effectively validate which new technologies work and for which specific hypertensive patient population.
Although several limitations preclude an accurate estimation of the prevalence of RH, this study characterizes the significant impact of accounting for optimal medication dosing on the prevalence of RH and provides a realworld context to the RDN trials. The retrospective nature of the study, however, does not allow for standardized outpatient BP recordings. It is also not possible to account for limitations in maximal medication dosing due to medication side effects, independent of BP. Approximately 25% of patients in this study were uncontrolled on only 2 antihypertensives, similar to 30% seen in the National Health and Nutrition Examination Survey 2003-2008 population, 10 suggesting possible underestimation of the RH prevalence should a substantial proportion of these patients remain uncontrolled with proper medication dosage titration. Given the retrospective nature of this study, dose titration was not possible. Spironolactone was relatively underused in patients with RH in our study (8.9%-16.7%), despite evidence of its effectiveness in similar patients. 5, 24 Initiation and titration of spironolactone would possibly have decreased the reported incidence of RH. Additionally, unidentified medication nonadherence, white-coat effect, and secondary causes of hypertension may account for possible overestimation of the true prevalence. 4, 9, 11 Our study also describes patients referred to cardiologists, which is likely to differ from a general population-based survey or one based in the primary care clinic setting. Some of these patients may have been prescribed evidence-based cardiovascular pharmacotherapy, such as beta blockers and ACE inhibitors, regardless of BP, which may also overestimate hypertensive prevalence.
Prevalence estimates of RH have been derived from studies using varying interpretations of the AHA definition. The estimated prevalence of RH, taking into account maximal medication dosing, may be considerably lower than what has previously been published. Patients with true, absolute treatment-resistant hypertension may represent a very small proportion of the overall hypertensive population. Consistent definitions of RH should be applied in the future to ensure that RH patients are correctly identified and that treatment interventions may be consistently compared.
Given the arbitrary nature of the current definition of RH and the inconsistency in its application, reclassifying the definition may better serve the purpose of identifying patients with RH that may benefit from further diagnostic or therapeutic measures. This applies directly to RDN, which has emerged as a treatment modality for RH. Our study demonstrates that based on currently published studies, the benefits of renal denervation can only be generalized to a very small population of hypertensive patients. The use of consistent RH definitions with more inclusive methodologic criteria may allow future studies to better understand who benefits from RDN and to possibly generalize this novel treatment modality to a wider range of RH patients.
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